<SEC-DOCUMENT>0001104659-21-117954.txt : 20210921
<SEC-HEADER>0001104659-21-117954.hdr.sgml : 20210921
<ACCEPTANCE-DATETIME>20210921171353
ACCESSION NUMBER:		0001104659-21-117954
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210921
DATE AS OF CHANGE:		20210921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		211267186

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2128162d1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SCHEDULE 14A INFORMATION</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Proxy Statement Pursuant
to Section&nbsp;14(a)&nbsp;of the Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Exchange Act of 1934</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Filed by the
Registrant&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
    Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential, for
    Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT> &nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional
    Materials</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material
    Pursuant to Section&nbsp;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Name of Person(s)&nbsp;Filing
Proxy Statement, if Other Than the Registrant)</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (check the appropriate box):</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required.</FONT></TD></TR>
  <TR STYLE="font-size: 8pt">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(1)&nbsp;and
    0-11.</FONT></TD></TR>
  <TR STYLE="font-size: 8pt">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class of securities to which transaction
    applies: &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: top">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate number of securities to which transaction
    applies: &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: top">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per unit price or other underlying value of transaction
    computed pursuant to Exchange Act Rule&nbsp;0-11 (Set forth the amount on which the filing fee is calculated and state how it was
    determined): &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: top">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed maximum aggregate value of transaction: &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: top">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fee paid: &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="font-size: 8pt">
    <TD STYLE="font-size: 8pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee paid previously
    with preliminary materials.</FONT></TD></TR>
  <TR STYLE="font-size: 8pt">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
    box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2)&nbsp;and identify the filing for which the
    offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form&nbsp;or Schedule and
    the date of its filing.</FONT></TD></TR>
  <TR STYLE="font-size: 8pt">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount Previously Paid: &nbsp; &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: top">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form, Schedule or Registration Statement No.: &nbsp;
    &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: top">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Party: &nbsp; &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: top">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Filed:</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: top">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt; border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2128162d1_defa14aimg01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September&nbsp;21, 2021, Synthetic Biologics,&nbsp;Inc.
filed the following Current Report on Form&nbsp;8-K and issued the related press release, which is furnished as Exhibit&nbsp;99.1 to
the Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):&nbsp;September&nbsp;21,
2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-12584</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13-3808303</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</P></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9605 Medical Center Drive, Suite&nbsp;270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockville, Maryland 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(301) 417-4364</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&nbsp;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which<BR>
 registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE
    American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule&nbsp;405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or
Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01.&#8239;&#8239;&#8239;&#8239;&#8239;Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September&nbsp;21,
2021, Synthetic Biologics,&nbsp;Inc. (the &ldquo;Company&rdquo;) convened  its 2021 Annual Meeting of Stockholders
(the &ldquo;Annual Meeting&rdquo;). At that time, there were not present or represented by proxy a sufficient number of shares of the
Company&rsquo;s common stock to constitute a quorum. <FONT STYLE="background-color: white">The Company adjourned the Annual Meeting,
which will reconvene at 9:30 a.m.&nbsp; Eastern Time on October&nbsp;6, 2021 </FONT>at the Company&rsquo;s corporate headquarters located
at 9605 Medical Center Drive, Suite&nbsp;270, Rockville, Maryland 20850.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The record date for
the Annual Meeting remains&nbsp;August&nbsp;9, 2021. Stockholders of the Company who have previously submitted their proxy or otherwise
voted and who do not want to change their vote do not need to take any action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">No changes have been
made in the proposals to be voted on by stockholders at the Annual Meeting. The Company strongly encourages all of its stockholders to
read the Company&rsquo;s definitive proxy statement on Schedule 14A, filed with the&nbsp;Securities and Exchange Commission&nbsp;(the
 &ldquo;SEC&rdquo;) on&nbsp;August&nbsp;16, 2021 (the &ldquo;Proxy Statement&rdquo;) and other proxy materials relating to the Annual
Meeting, which are available free of charge on the&nbsp;SEC&rsquo;s&nbsp;website at&nbsp;<I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current adjournment, the Company will
continue to solicit votes from its stockholders with respect to the proposals set forth in the Proxy Statement. As set forth in the Proxy
Statement, the Company has engaged a proxy solicitor, D.F. King&nbsp;&amp; Co.,&nbsp;Inc. to assist management with obtaining adequate
votes to achieve the required quorum of at least a majority of the outstanding shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September&nbsp;21,
2021, the Company issued a press release to announce the adjournment, which is furnished as Exhibit&nbsp;99.1 to this Current Report
on Form&nbsp;8-K. The information in the press release furnished as Exhibit&nbsp;99.1 hereto shall not be deemed &ldquo;filed&rdquo;
for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject
to the liabilities of that section, or incorporated by reference into any of the Company&rsquo;s filings under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.&#8239;&#8239;&#8239;&#8239;&#8239;Financial Statements
and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 97%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release of Synthetic Biologics,&nbsp;Inc., dated
    September&nbsp;21, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cover
    Page&nbsp;Interactive Data File (embedded within the XBRL document)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: September&nbsp;21, 2021</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer and Chief Financial Officer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2128162d1_defa14aimg02.jpg" ALT="" STYLE="height: 76px; width: 250px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Announces Adjournment of
Annual Meeting of Shareholders Due to Lack of Quorum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, September&nbsp;21, 2021 &ndash;
</B><U>Synthetic Biologics,&nbsp;Inc.</U> (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop
therapeutics designed to prevent and treat gastrointestinal (&ldquo;GI&rdquo;) diseases in areas of high unmet need, today announced
that the Company&rsquo;s annual meeting of shareholders, on September&nbsp;21, 2021, at 9:30 a.m.&nbsp;ET was convened and adjourned,
without any business being conducted, due to lack of the required quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A quorum consists of a majority of the shares
entitled to vote. There were fewer than a majority of shares entitled to vote present, either in person or by proxy at this meeting.
Approximately 46.2% of the shares of the Company&rsquo;s common stock outstanding as of the record date were properly voted at the time
of the annual meeting. The annual meeting of shareholders therefore had no quorum and the meeting was adjourned and will reconvene at
9:30 a.m.&nbsp;ET on Wednesday, October&nbsp;6, 2021 at the Company&rsquo;s corporate headquarters 9605 Medical Center Drive, Suite&nbsp;270,
Rockville, MD 20850 to allow additional time for the Company&rsquo;s shareholders to vote on the proposals set forth in the Company&rsquo;s
definitive proxy statement filed with the United States Securities and Exchange Commission (the &ldquo;S.E.C.&rdquo;) on August&nbsp;16,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current adjournment, the Company will
continue to solicit votes from its shareholders with respect to the proposals set forth in the Company&rsquo;s proxy statement. As set
forth in the proxy statement, the Company has engaged a proxy solicitor, D.F. King&nbsp;&amp; Co.,&nbsp;Inc. to assist management with
obtaining adequate votes to achieve the required quorum of at least a majority of the outstanding shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company encourages all shareholders of record,
as of the record date August&nbsp;9, 2021, who have not yet voted, to do so by October&nbsp;5, 2021 at 11:59 p.m.&nbsp;ET. Shareholders
who have any questions or require any assistance with completing a proxy or voting instruction form or who do not have the required materials,
may contact D.F. King&nbsp;&amp; Co.,&nbsp;Inc. using the following contact information 48 Wall Street, 22<SUP>nd</SUP> Floor, New York,
NY 10005, Telephone: Toll Free: 1-800-859-8509 and Outside North America: +1-212-269-5550. Email: <U>synthetic@dfking.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics,&nbsp;Inc. (NYSE American:
SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need. The Company&rsquo;s lead candidates are: (1)&nbsp;SYN-004 (ribaxamase) which is designed to
degrade certain commonly used intravenous (IV)&nbsp;beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a)&nbsp;microbiome
damage, (b)&nbsp;<I>Clostridioides difficile</I> infection (CDI), (c)&nbsp;overgrowth of pathogenic organisms, (d)&nbsp;the emergence
of antimicrobial resistance (AMR), and (e)&nbsp;acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT)
recipients, and (2)&nbsp;SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP
conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website
at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified
by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions. These forward-looking statements
are based on management&rsquo;s expectations and assumptions as of the date of this press release and are subject to a number of risks
and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results
to differ materially from current expectations include, among others, the ability of Synthetic Biologics to receive the necessary regulatory
approvals for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo; clinical trials,
and those conducted by investigators, for SYN-004 and SYN-020 to be commenced or completed on time, to provide topline data when anticipated
or to achieve desired results and benefits, especially in light of COVID-19, a failure of Synthetic Biologics&rsquo; clinical trials
to continue enrollment as expected or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or
sell its products, Synthetic Biologics&rsquo; inability to maintain its material licensing agreements, or a failure by Synthetic Biologics
or its strategic partners to successfully commercialize products and other factors described in Synthetic Biologics&rsquo; Annual Report
on Form&nbsp;10-K for the year ended December&nbsp;31, 2020 and its other filings with the SEC, including subsequent periodic reports
on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes
no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics,&nbsp;Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240) 660-2000,
<U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2128162d1_defa14aimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128162d1_defa14aimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  J (L# 2(  A$! Q$!_\0
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1&:5I8K%RNYMS?K+?]%Z(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2128162d1_defa14aimg02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128162d1_defa14aimg02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !< 3 # 2(  A$! Q$!_\0
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MV]V_,_I2.&44HQ5DCIO#?A_5/&.HBTTFPO-2N3SY=M"TC =,G'0>YXJYXT\
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MCG( /S=:]5_9Y_9K\#?LI?#>W\)?#WPY8^&= MW:;[/;[F:61L!I))'+/(Y
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..N%%%%?8GYH%%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
